You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

mGlu5 receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDD, Treatment-Resistant Depression, Depression Trial run by the NIMH (Placebo, TS-161 (50 - 100 mg))

Recruiting
  • Major Depressive Disorder
  • +2 more
  • Placebo
  • TS-161 (50 - 100 mg)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Parkinson Disease Trial in Bron, Lyon (neuropsychological assessment, biological sample, medical imagery)

Not yet recruiting
  • Parkinson Disease
  • neuropsychological assessment
  • +2 more
  • Bron, France
  • +1 more
Jun 13, 2023

Implication of 5-HT7 Receptor in Inflammatory Mechanisms in

Not yet recruiting
  • Healthy
  • Multiple Sclerosis
  • Blood sample
  • Orléans, France
    CHR Orléans
Feb 16, 2023

Pediatric Cancer Trial in Yerevan (Ondansetron, Dexamethasone)

Not yet recruiting
  • Pediatric Cancer
  • Yerevan, Armenia
    Hematology Center named after prof. R. Yeolyan
May 23, 2023

Primary Aldosteronism Trial in Montréal (Renin measurements)

Not yet recruiting
  • Primary Aldosteronism
  • Renin measurements
  • Montréal, Quebec, Canada
    Hôpital du Sacré-Coeur de Montréal
Oct 30, 2023

LARS - Low Anterior Resection Syndrome Trial in Seoul (Ramosetron)

Not yet recruiting
  • LARS - Low Anterior Resection Syndrome
  • Seoul, Jongro-gu, Korea, Republic of
    Seoul National University Hospital
Dec 13, 2022

Healthy Trial in Leeds (HTL0014242, Placebo oral capsule)

Completed
  • Healthy
  • Leeds, West Yorkshire, United Kingdom
    Covance
Apr 27, 2021

Breast Cancer, Chemo-induced Nausea and Vomiting Trial in Hanzhou (Aprepitant, Palonosetron, Fosaprepitant)

Not yet recruiting
  • Breast Cancer
  • Chemotherapy-induced Nausea and Vomiting
  • Hanzhou, Zhejiang, China
    the Second Affiliated Hospital of Zhejiang Univercity School of
Apr 23, 2023

Depressive Disorder, Major, Bipolar Disorder, Post Traumatic Stress Disorder Trial in New Haven (Ketamine, Perampanel, Placebo)

Not yet recruiting
  • Depressive Disorder, Major
  • +2 more
  • New Haven, Connecticut
    Yale University
Jun 26, 2023

Postpartum Hemorrhage Trial in Toronto (Oxytocin)

Recruiting
  • Postpartum Hemorrhage
  • Toronto, Ontario, Canada
    Mount Sinai Hospital
Oct 24, 2022

Multiple Myeloma Trial in New York (Infusion of MCARH109 T cells)

Active, not recruiting
  • Multiple Myeloma
  • Infusion of MCARH109 T cells
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 5, 2022

Aortic Stenosis Trial in Québec, Odense (Angiotensin Receptor Blockers, Placebo)

Recruiting
  • Aortic Stenosis
  • Angiotensin Receptor Blockers
  • Placebo
  • Québec, Quebec, Canada
  • +1 more
Mar 28, 2022

5-HT7 Receptor Implication in Inflammatory Mechanisms in

Completed
  • Multiple Sclerosis, Acute Relapsing
  • Multiple Sclerosis
  • blood sampling
  • Orléans, France
    CHR Orléans
Feb 16, 2022

Depressive Disorder, Major, Bipolar Disorder, Post Traumatic Stress Disorder Trial in New Haven (Ketamine, Perampanel, Placebo)

Recruiting
  • Depressive Disorder, Major
  • +2 more
  • New Haven, Connecticut
    Yale University
Aug 8, 2022

Acute Respiratory Distress Syndrome Trial in Montréal (Placebo, Ondansetron Injection)

Not yet recruiting
  • Acute Respiratory Distress Syndrome
  • Placebo
  • Ondansetron Injection
  • Montréal, Quebec, Canada
    Hôpital Sacré-Coeur de Montréal
Aug 22, 2022

Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary Trial in Brescia, Genova (Letrozole tablets, carboplatin

Recruiting
  • Carcinoma, Ovarian Epithelial
  • Low Grade Serous Adenocarcinoma of Ovary
  • Letrozole tablets
  • carboplatin AUC 5 and paclitaxel 175 mg/m2
  • Brescia, BS, Italy
  • +1 more
Oct 26, 2022

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

Recruiting
  • Malignant Pleural Mesothelioma, Advanced
  • Oncolytic Adenovirus H101
  • Programmed death receptor-1 inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical Unversity Second Hospital
Sep 2, 2023

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

Active, not recruiting
  • Estrogen Receptor-positive Breast Cancer
  • +5 more
  • PI3K inhibitor BYL719
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 14, 2022

Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer Trial in Boston

Completed
Has Results
  • Breast Cancer Stage IV
  • +2 more
  • Boston, Massachusetts
  • +1 more
Oct 21, 2022

Lung Fluid and Peripheral Blood Neutrophil IL-5 Surface Receptor

Completed
  • Asthma
  • Bronchoscopy
  • Charlottesville, Virginia
    University of Virginia Health System
Feb 4, 2022

Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor Trial in Vancouver (177Lu-DOTATOC)

Not yet recruiting
  • Neuroendocrine Tumors
  • +6 more
  • Vancouver, British Columbia, Canada
    BC Cancer
Aug 19, 2022

Breast Cancer Trial in Poland, United States (ZN-c5, Abemaciclib)

Recruiting
  • Breast Cancer
  • Gilbert, Arizona
  • +6 more
Feb 14, 2022

Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia Trial (HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5%

Not yet recruiting
  • Acneiform Eruption Due to Chemical
  • +2 more
  • HT-001 2% Topical Gel
  • +3 more
  • (no location specified)
Dec 3, 2022

Familial Alcoholism Vulnerability Trial in Hartford (Mavoglurant (AFQ056), Placebo)

Completed
  • Familial Alcoholism Vulnerability
  • Mavoglurant (AFQ056)
  • Placebo
  • Hartford, Connecticut
    Hartford Hospital
Jan 7, 2022

Breast Cancer, Breast Tumor Trial in Philadelphia ([18F]ISO-1)

Active, not recruiting
  • Breast Cancer
  • Breast Neoplasm
  • Philadelphia, Pennsylvania
    University of Pennsylvania Hospital
Jan 17, 2023